Hubei Jumpcan Pharmaceutical Future Growth
Future criteria checks 1/6
Hubei Jumpcan Pharmaceutical is forecast to grow earnings and revenue by 10% and 10.7% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 17.8% in 3 years.
Key information
10.0%
Earnings growth rate
9.6%
EPS growth rate
Pharmaceuticals earnings growth | 19.2% |
Revenue growth rate | 10.7% |
Future return on equity | 17.8% |
Analyst coverage | Low |
Last updated | 23 Aug 2023 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 12,289 | 3,108 | N/A | 3,719 | 2 |
12/31/2024 | 11,069 | 2,769 | N/A | 2,582 | 2 |
12/31/2023 | 10,038 | 2,489 | N/A | 3,179 | 2 |
9/30/2023 | 9,639 | 2,523 | 3,156 | 3,458 | N/A |
6/30/2023 | 9,762 | 2,495 | 3,104 | 3,354 | N/A |
3/31/2023 | 9,211 | 2,266 | 2,733 | 2,916 | N/A |
12/31/2022 | 8,996 | 2,171 | 2,377 | 2,621 | N/A |
9/30/2022 | 8,115 | 2,039 | 2,080 | 2,321 | N/A |
6/30/2022 | 7,811 | 1,881 | 1,899 | 2,135 | N/A |
3/31/2022 | 7,888 | 1,861 | 1,888 | 2,172 | N/A |
12/31/2021 | 7,631 | 1,719 | 1,646 | 1,894 | N/A |
9/30/2021 | 7,260 | 1,590 | 1,672 | 1,949 | N/A |
6/30/2021 | 6,896 | 1,446 | 1,485 | 1,827 | N/A |
3/31/2021 | 6,074 | 1,252 | 1,404 | 1,805 | N/A |
12/31/2020 | 6,165 | 1,277 | 1,352 | 1,782 | N/A |
9/30/2020 | 5,868 | 1,277 | 1,304 | 1,793 | N/A |
6/30/2020 | 5,984 | 1,344 | 1,724 | 2,228 | N/A |
3/31/2020 | 6,868 | 1,577 | 1,725 | 2,231 | N/A |
12/31/2019 | 6,940 | 1,623 | 1,601 | 2,148 | N/A |
9/30/2019 | 7,050 | 1,685 | 1,463 | 1,935 | N/A |
6/30/2019 | 7,311 | 1,809 | 1,251 | 1,787 | N/A |
3/31/2019 | 7,160 | 1,731 | 1,210 | 1,781 | N/A |
12/31/2018 | 7,208 | 1,688 | 1,041 | 1,709 | N/A |
9/30/2018 | 6,972 | 1,625 | 934 | 1,753 | N/A |
6/30/2018 | 6,636 | 1,484 | 701 | 1,500 | N/A |
3/31/2018 | 6,365 | 1,400 | 550 | 1,399 | N/A |
12/31/2017 | 5,642 | 1,223 | 443 | 1,189 | N/A |
9/30/2017 | 5,385 | 1,165 | 599 | 1,240 | N/A |
6/30/2017 | 5,134 | 1,076 | N/A | 1,161 | N/A |
3/31/2017 | 4,926 | 1,016 | N/A | 971 | N/A |
12/31/2016 | 4,678 | 934 | N/A | 913 | N/A |
9/30/2016 | 4,458 | 864 | N/A | 764 | N/A |
6/30/2016 | 4,249 | 796 | N/A | 779 | N/A |
3/31/2016 | 4,020 | 736 | N/A | 751 | N/A |
12/31/2015 | 3,768 | 687 | N/A | 645 | N/A |
9/30/2015 | 3,585 | 640 | N/A | 688 | N/A |
6/30/2015 | 3,392 | 595 | N/A | 662 | N/A |
3/31/2015 | 3,178 | 553 | N/A | 570 | N/A |
12/31/2014 | 2,986 | 519 | N/A | 616 | N/A |
9/30/2014 | 2,829 | 490 | N/A | 589 | N/A |
6/30/2014 | 2,664 | 461 | N/A | 329 | N/A |
3/31/2014 | 2,524 | 429 | N/A | 326 | N/A |
12/31/2013 | 2,448 | 403 | N/A | 287 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600566's forecast earnings growth (10% per year) is above the savings rate (2.9%).
Earnings vs Market: 600566's earnings (10% per year) are forecast to grow slower than the CN market (27% per year).
High Growth Earnings: 600566's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600566's revenue (10.7% per year) is forecast to grow slower than the CN market (15.2% per year).
High Growth Revenue: 600566's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600566's Return on Equity is forecast to be low in 3 years time (17.8%).